Abstract
The receptor tyrosine kinase c-Met has multiple roles during cancer development and is currently considered as a promising target for cancer therapies. Pharmacophore models of c-Met kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio program package. The best quantitative pharmacophore model, Hypo 1, which had the highest correlation coefficient (0.9623), consists of two hydrogen bond acceptors, one hydrophobic feature and two excluded volumes. Then best model was validated by test set prediction, Fischer randomization and decoy set. Besides, the features of Hypo1 were verified to correctly reflect the interactions between kinase active site and its ligands by comparison and superimposition of Hypo 1 in active site of c-Met kinase. The results shows that Hypo 1 has strong capability to identify c-Met kinase inhibitors and to predict the activities of structurally diverse molecules. Therefore, our pharmacophore models were considered as valuable tools for the discovery and development of specific c-Met kinase inhibitors.
Keywords: Anticancer, c-Met kinase, Discovery Studio, HypoGen, Pharmacophore modeling, Quantitative structure-activity relationship
Medicinal Chemistry
Title:3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Volume: 8 Issue: 6
Author(s): Dandan Huang, Xiaoyun Zhu, Chunlei Tang, Yicheng Mei, Wei Chen, Baowei Yang, Jing Han, Hai Qian and Wenlong Huang
Affiliation:
Keywords: Anticancer, c-Met kinase, Discovery Studio, HypoGen, Pharmacophore modeling, Quantitative structure-activity relationship
Abstract: The receptor tyrosine kinase c-Met has multiple roles during cancer development and is currently considered as a promising target for cancer therapies. Pharmacophore models of c-Met kinase inhibitors have been developed based on 22 diverse compounds by using HypoGen algorithm implemented in Discovery studio program package. The best quantitative pharmacophore model, Hypo 1, which had the highest correlation coefficient (0.9623), consists of two hydrogen bond acceptors, one hydrophobic feature and two excluded volumes. Then best model was validated by test set prediction, Fischer randomization and decoy set. Besides, the features of Hypo1 were verified to correctly reflect the interactions between kinase active site and its ligands by comparison and superimposition of Hypo 1 in active site of c-Met kinase. The results shows that Hypo 1 has strong capability to identify c-Met kinase inhibitors and to predict the activities of structurally diverse molecules. Therefore, our pharmacophore models were considered as valuable tools for the discovery and development of specific c-Met kinase inhibitors.
Export Options
About this article
Cite this article as:
Huang Dandan, Zhu Xiaoyun, Tang Chunlei, Mei Yicheng, Chen Wei, Yang Baowei, Han Jing, Qian Hai and Huang Wenlong, 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors, Medicinal Chemistry 2012; 8 (6) . https://dx.doi.org/10.2174/1573406411208061117
DOI https://dx.doi.org/10.2174/1573406411208061117 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends
Current Reviews in Clinical and Experimental Pharmacology Research Advances on Anticancer Effect of Licorice
Current Bioactive Compounds Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design CT Findings of Pulmonary Metastases from Primary Cardiac Angiosarcoma
Current Medical Imaging Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
Current Cancer Drug Targets Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters Electrotransfer as a Non Viral Method of Gene Delivery
Current Gene Therapy Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Synthetic Peptides Derived from the C-Terminal Region of Lys49 Phospholipase A2 Homologues from Viperidae Snake Venoms: Biomimetic Activities and Potential Applications
Current Pharmaceutical Design miRNA 21: Diagnostic Prognostic and Therapeutic Marker for Oral Cancer
MicroRNA The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review
Current Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Defects in RNA Metabolism links FTD and ALS Pathogenesis: TDP-43, FUS, and C9orf72
Current Enzyme Inhibition Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Exploring Protein-Protein and Protein-Ligand Interactions in the Immune System using Molecular Dynamics and Continuum Electrostatics
Current Physical Chemistry